- Home
- Â /Â Lundbeck
Lundbeck
Stock Price
KR36.3
2024-10-29
Market Capitalization
KR43 B
2024-10-29
Revenue
KR22 B
FY, 2024
Lundbeck Summary
Company Summary
- Overview
- H. Lundbeck is a pharmaceutical company specializing in brain diseases. It is engaged in research, development, manufacturing, and commercialization of pharmaceuticals.
- Type
- Public
- Status
- Active
- Founded
- 1915
- HQ
- København, DK | view all locations
- Website
- https://www.lundbeck.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Joerg Hornstein, CFO & Executive Vice President, Corporate Functions
Dianne Hol, Executive Vice President, People & Organization
Tine Østergaard Hansen, Senior Vice President, Corporate Communications & Public Affairs
Operating MetricsView all
Trademarks
2.7K
May, 2024
Countries
100
May, 2024
Trademark Applications
212
May, 2024
LocationsView all
48 locations detected
København HQ
Denmark
Ottiliavej 9
Deerfield, IL
United States
6 Parkway N
Buenos Aires, Cdad. Autónoma de Buenos Aires
Argentina
Heredia 553
North Ryde, NSW
Australia
Innovation Rd
Wien, Wien
Austria
Spaces Square One Leopold Ungar Platz 2
Bruxelles, Bruxelles
Belgium
Stephanie Square Centre Louizalaan/Avenue Louise 65, Box 11
Lundbeck Financials
Summary Financials
- Revenue (FY, 2024)
- kr22.0B
- Gross profit (FY, 2024)
- kr19.5B
- Net income (FY, 2024)
- kr3.1B
- Cash (FY, 2024)
- kr4.7B
- EBIT (FY, 2024)
- kr3.3B
- Enterprise value
- $55.0B